Suki Raises $90M for Planned Healthcare AI Agents

On October 13, 2026, Redwood City-based Suki announced a $90 million Series E, taking its total funding above $250 million, according to Fierce Healthcare. New investors Healthier Capital, Crosslink Capital and Hercules Capital joined existing backers including Venrock, Flare Capital Partners, Hedosophia, Philips Ventures and Zoom Ventures. The capital is intended to advance Suki’s AI, expand its commercial organization and deepen its technology partnerships.

The proposed expansion reaches beyond the clinical note into work triggered by a treatment plan. In a Healthcare Dive interview, founder and CEO Punit Soni described plans for agents handling referrals and prior authorizations, alongside order entry and follow-up scheduling; of the partner strategy, he said, “We want to go deep with them.” Those agents are development plans, while Suki’s existing products already handle some narrower steps in clinical workflows.

What the planned agents would change after a visit

A referral begins with a clinical decision but must become a usable handoff to another service. An agent drawing on information captured during the encounter could help assemble the reason for referral and relevant patient context, reducing the need to enter the same details again. The consequential step is getting that information into the receiving workflow; a completed note alone does not arrange specialist care.

Prior authorization creates a different handoff. When a prescribed medication requires a payer’s approval, the request needs clinical information that supports the proposed treatment. An agent could help prepare that material from the encounter and chart, but the payer would still decide coverage. The financing news describes this as a planned task; it does not establish that an authorization agent is deployed or specify who would review a prepared request before submission.

Orders and follow-ups sit closer to the clinician’s immediate plan. An order has to become structured information in the health record, while a follow-up requires an appointment to be scheduled rather than merely mentioned in a note. These tasks have different destinations and checkpoints, so treating them as a single automatic action would obscure what remains for a clinician, scheduling staff or another system to complete. Suki has identified the work it wants agents to perform without giving a rollout date for the proposed post-visit set.

Existing tools show where human review sits today

Suki already offers a narrower form of order automation. Its orders product page says the system stages structured orders from ambient visits in Epic or athenahealth for clinician review and signature, and lists more than 300 organizations across those systems. Orders can be staged when the conversation ends, before the rest of the note is finished. The product does not submit them automatically: the clinician checks the proposed order and owns the clinical decision.

That distinction matters for the planned order agent. Preparing fields can remove manual entry while leaving approval with the clinician; completing an order workflow would require clear rules about what the software may do after that review. The existing product supplies a concrete example of a human checkpoint, but it does not define the permissions or sign-off process for every future agent.

Suki has also released a tool aimed at decisions during care rather than administrative completion afterward. An October 8 Ask announcement states that Ask is available in Suki for Clinicians across Epic, Oracle Health, athenahealth and MEDITECH. Clinicians can ask about chart details such as medications, allergies and lab results; those with UpToDate access can also receive answers grounded in Wolters Kluwer’s clinical content. Ask helps surface information for a decision. The proposed agents would address tasks that follow from it.

The financing builds on two routes into healthcare systems

Suki has a direct clinician product and a separate embedded-technology business. In its Series E release, Suki says its clinician-facing app serves more than 450 healthcare organizations, more than 30 technology partners embed its AI, supported patient encounters grew more than 190% year over year in 2026, and partner revenue increased more than tenfold over the past two years. The organization count describes the app’s reach; the partner count describes companies incorporating Suki technology into their own products. The growth figures are company-reported and do not disclose a revenue total.

That distribution shapes what the new money can finance. Adding an agent to Suki’s own app would reach one set of users; making the same capability work inside a partner product requires integration with that product’s data, actions and approval process. athenahealth’s Ambient Notes and Zoom’s telehealth documentation feature already use Suki technology, while Optum is also among its named technology relationships. The funding plan therefore depends on extending existing connections as well as developing the agents themselves.

Healthier Capital partner Aman Mahajan is set to join Suki’s board as part of the financing. For health systems, the next meaningful evidence will be a named deployment that shows which post-visit task an agent completes, where its output goes and who authorizes the final action.